Exact enlists Pfizer to boost Cologuard sales

Exact Sciences Corp. (NASDAQ:EXAS) gained $15.27 (31%) to $65.32 on Aug. 22 after partnering with Pfizer Inc. (NYSE:PFE) to co-promote Exact's Cologuard in the U.S.

Exact hopes the partnership will drive adoption of the non-invasive stool DNA test for colorectal cancer. The deal comes three weeks after the biotech reported completed Cologuard test volumes for 2Q18 that lagged behind Street expectations and sent its stock tumbling (see "Exact Slides After Cologuard Volume Disappoints")...